Loading
Life sciences · Journal article
Frontiers in Digital Health · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction While current guidelines recommend screening for liver disease in target populations, existing non-invasive tests have limitations in identifying at-risk metabolic dysfunction-associated steatohepatitis (MASH). Materials and methods This retrospective study used two large datasets from the general population in the Valencian Community region (Spain). The primary goal was to develop a machine learning model to identify individuals with at-risk MASH. The model was constructed using a well-characterized dataset ( n = 2,267) with available vibration-controlled transient elastography (VCTE). Supervised machine learning models (Random Forest and XGBoost) were trained using a 10-fold cross-validation to classify at-risk MASH individuals, defined as those with a controlled attenuation parameter (CAP) ≥ 275 dB/m together with a liver stiffness measurement (LSM) > 8 kPa and/or FibroScan-AST score (FAST) > 0.35. The final model, named VARM-7 (Valencia At-Risk MASH), comprised age and six commonly available laboratory variables. VARM-7 was sequentially applied to the Valencian public healthcare database ( n = 3,411,069) to estimate the proportion of at-risk MASH individuals in the overall population, and in target populations with type 2 diabetes mellitus (T2DM) and obesity. Results In the independent validation dataset, VARM-7 exhibited a significantly higher AUROC compared with Fibrosis-4 (FIB-4) for identifying at-risk MASH (0.84 vs. 0.64, respectively, p < 0.001). When sequentially applied to the overall Valencian Community population, 11.7% of individuals were estimated to have at-risk MASH, with increasing estimates up to 29.4% and 44.0% in subjects with obesity and T2DM, respectively. Conclusion VARM-7 showed strong performance in identifying individuals with a VCTE-derived at-risk MASH. Our model could improve disease screening and referral pathways, but external validation and prognostic evaluation are needed before its implementation.